Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.
BACKGROUND: Systemic sclerosis (SSc) is characterized by excessive fibrosis and obliterative vascular lesions. Abnormal TGFbeta activation is implicated in the pathogenesis of SSc. Aberrant TGFbeta/Smad signaling can be controlled by stabilization of microtubules with paclitaxel. METHODS AND FINDING...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2005-12-01
|
| Series: | PLoS Medicine |
| Online Access: | http://europepmc.org/articles/PMC1274282?pdf=render |